Market Exclusive

Analyst Activity – Leerink Swann Reiterates Outperform on Puma Biotechnology (NYSE:PBYI)

Analyst Ratings For Puma Biotechnology (NYSE:PBYI)

Today, Leerink Swann reiterated its Outperform rating on Puma Biotechnology (NYSE:PBYI) with a price target of $125.00.

There are 1 hold rating, 7 buy ratings on the stock.

The current consensus rating on Puma Biotechnology (NYSE:PBYI) is Buy (Score: 2.88) with a consensus target price of $103.63 per share, a potential 10.89% upside.

Some recent analyst ratings include

Recent Insider Trading Activity For Puma Biotechnology (NYSE:PBYI)
Puma Biotechnology (NYSE:PBYI) has insider ownership of 22.70% and institutional ownership of 80.98%.

Recent Trading Activity for Puma Biotechnology (NYSE:PBYI)
Shares of Puma Biotechnology closed the previous trading session at 93.45 0.00 0.00% with 3,408,423 shares trading hands.

Exit mobile version